Park Avenue Securities’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $560K | Sell |
2,321
-70
| -3% | -$16.9K | 0.01% | 1016 |
|
|
2025
Q1 | $582K | Buy |
2,391
+100
| +4% | +$24.3K | 0.01% | 802 |
|
|
2024
Q4 | $753K | Buy |
2,291
+504
| +28% | +$166K | 0.01% | 893 |
|
|
2024
Q3 | $598K | Sell |
1,787
-377
| -17% | -$126K | 0.01% | 911 |
|
|
2024
Q2 | $591K | Sell |
2,164
-56
| -3% | -$15.3K | 0.01% | 892 |
|
|
2024
Q1 | $768K | Buy |
2,220
+205
| +10% | +$70.9K | 0.01% | 785 |
|
|
2023
Q4 | $651K | Sell |
2,015
-1,578
| -44% | -$510K | 0.01% | 800 |
|
|
2023
Q3 | $1.29M | Buy |
+3,593
| New | +$1.29M | 0.02% | 464 |
|
|
2023
Q1 | – | Sell |
-3,067
| Closed | -$1.29M | – | 749 |
|
|
2022
Q4 | $1.29M | Buy |
3,067
+298
| +11% | +$125K | 0.02% | 419 |
|
|
2022
Q3 | $1.16M | Buy |
2,769
+175
| +7% | +$73K | 0.02% | 404 |
|
|
2022
Q2 | $1.28M | Buy |
2,594
+342
| +15% | +$169K | 0.02% | 381 |
|
|
2022
Q1 | $1.27M | Sell |
2,252
-57
| -2% | -$32.1K | 0.02% | 399 |
|
|
2021
Q4 | $1.75M | Buy |
2,309
+33
| +1% | +$24.9K | 0.03% | 302 |
|
|
2021
Q3 | $1.7M | Buy |
2,276
+85
| +4% | +$63.4K | 0.03% | 276 |
|
|
2021
Q2 | $1.41M | Buy |
2,191
+108
| +5% | +$69.6K | 0.03% | 294 |
|
|
2021
Q1 | $1.19M | Buy |
2,083
+568
| +37% | +$324K | 0.03% | 295 |
|
|
2020
Q4 | $883K | Buy |
1,515
+122
| +9% | +$71.1K | 0.02% | 321 |
|
|
2020
Q3 | $718K | Buy |
1,393
+169
| +14% | +$87.1K | 0.02% | 305 |
|
|
2020
Q2 | $553K | Buy |
1,224
+407
| +50% | +$184K | 0.02% | 371 |
|
|
2020
Q1 | $286K | Buy |
817
+117
| +17% | +$41K | 0.02% | 244 |
|
|
2019
Q4 | $259K | Buy |
+700
| New | +$259K | 0.01% | 504 |
|